- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- OncNursingNews.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Hematology | Clinical
Recommendations for Diagnosing and Treating Rare Histiocytic Neoplasms
September 08, 2022
Ronald S. Go, MD, discusses what community oncologists should know regarding the guidelines on managing patients with histiocytic neoplasms.
FDA Approves a New Pegfilgrastim Biosimilar for Febrile Neutropenia
September 07, 2022
Pegfilgrastim-fpgk has been approved by the FDA for patients with febrile neutropenia following data which revealed it to have a high degree of similarity with its reference product.
First-Line Pivekimab Sunirine Elicits Favorable Responses in BPDCN
September 01, 2022
Data from the phase 2 CADENZA trial revealed front-line pivekimab sunirine to demonstrate clinical activity in patients with blastic plasmacytoid dendritic cell neoplasm.
Unmet Needs for Managing CRS and ICANS Due to CAR T-Cell Therapy
September 01, 2022
Nicolas Gazeau, MS, discusses next steps and unmet needs following a positive retrospective study of anakinra for the management of neurotoxicity and cytokine release syndrome in patients who received chimeric antigen receptor T-cell therapy.
Future Directions for NK Cell Platforms in Hematologic Malignancies
August 30, 2022
Jeffrey Miller, MD, discusses what is next to come following an analysis of GTB-3550.
FDA Clears IND for CNTY-101 in Relapsed/Refractory CD19 Positive B-cell Malignancies
August 29, 2022
An investigational new drug application has been accepted by the FDA allowing for the start of a phase 1 trial to evaluate the tolerability of CNTY-101 in patients with relapsed or refractory CD19 positive B-cell malignancies
FDA Approves Pemigatinib for R/R FGFR1+ Myeloid/Lymphoid Neoplasms
August 26, 2022
Approval has been granted by the FDA to pemigatinib for the treatment of patients with myeloid/lymphoid neoplasms with FGFR1 rearrangement based on the phase 2 FIGHT-203 trial.
Couriel Assesses the Available Data for Treatment of Acute GVHD
August 26, 2022
During a Targeted Oncology case-based roundtable event, Daniel R. Couriel, MD, MS, MBA, discussed how to predict risk of acute graft-vs-host-disease and manage its effects on patients with hematologic malignancies.
FDA Approves Ibrutinib for Previously Treated Peds and Young Adults With cGVHD
August 24, 2022
Findings from.the phase 1/2 IMAGINE have led the FDA to approve ibrutinib for select pediatric and young adult patients with chronic graft-versus-host disease.
FDA Approves Betibeglogene Autotemcel for Beta-Thalassemia Treatment in Adults and Children
August 17, 2022
Approval has been granted by the FDA to betibeglogene autotemcel for the treatment of patients with beta-thalassemia based on multiple phase 3 studies.